GAITHERSBURG, Md. and CARLSBAD, Calif., Aug. 21, 2006 (PRIMEZONE) -- MedImmune, Inc. (Nasdaq:MEDI) and Micromet, Inc. (Nasdaq:MITI) today announced that MedImmune has filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) for MT103 (also known as MEDI-538) for the treatment of patients with B-cell-derived non-Hodgkins lymphoma (NHL) not eligible for curative therapy. MT103 is a recombinant single-chain bispecific T-cell engager, or BiTE(R), molecule. It targets the CD19 antigen, which is uniquely expressed on B cells.
